Lipocine Reaches Milestone in Phase 3 Study for Postpartum Depression Treatment Lipocine Inc. has achieved 80% enrollment in its Phase 3 clinical trial for LPCN 1154, an innovative treatment for postpartum depression (PPD).

Lipocine Reaches Milestone in Phase 3 Study for Postpartum Depression Treatment #USA #Salt_Lake_City #Lipocine #LPCN_1154 #PPD_Treatment